image: Clinical relevance evaluation of a novel homologous recombination deficiency CE-IVD decentralized solution that identifies ovarian cancer patients that could potentially benefit from PARP-inhibitors. view more
Credit: NA
BOSTON, United States and LAUSANNE, Switzerland – November 2, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, debuted new data at the European Society of Gynaecological Oncology (ESGO) Congress as part of a poster (#PA-065) presented by Prof. Alexandre Harlé of the Institut de Cancérologie de Lorraine, France. The results show an evaluation of Homologous Recombination (HRD) detection supported by a deep learning algorithm in a clinical cohort of ovarian cancer patients treated with a PARP inhibitor.* The new evaluation data show the clinical utility of the SOPHiA DDM™ Dx HRD Solution for accurate HRD testing.
The deep learning-based solution expands identification possibilities for HRD-positive ovarian cancer patients that could potentially benefit from first-line maintenance therapy with PARP inhibitors. In a single workflow, the SOPHiA DDM™ Dx HRD Solution can evaluate the causes and the consequences of HRD, which is a complex biomarker with predictive value in ovarian cancer. Approximately half of all newly diagnosed patients with advanced ovarian cancer have HRD-positive tumors.
The clinical relevance of the SOPHiA DDM™ Dx HRD Solution presented at ESGO was evaluated in a multicenter study using a sub-set of ovarian cancer samples[1]. The results demonstrate that median progression-free survival (PFS) was improved in PARPi-treated patients with HRD-positive status as detected by the SOPHiA DDMTM Dx HRD Solution*. The information presented at ESGO can be found at this page.
The SOPHiA DDM™ Dx HRD Solution is CE-IVD certified, enabling it to inform diagnostic purposes in the European Union and other markets recognizing this certification.
SOPHiA GENETICS empowers medical institutions to implement a decentralized testing approach for ovarian cancer management. Rather than having to send tests to larger laboratories, they can simplify and expedite the process in-house, allowing them to retain ownership of the data analyzed, in a cost-effective, timely and reliable manner to potentially allow for better therapy decisions.
*Interim results based on retrospective correlation findings outside the context of a clinical trial
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
[1] PAOLA-1 ClinicalTrials.gov number, NCT02477644. Ray-Coquard I, Pautier P, Pignata S, et al. N Engl J Med. 2019;381(25):2416-2428.
Method of Research
News article